- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress | 317 | ACCESS Newswire | Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline... ► Artikel lesen | |
| 14.05. | CNS Pharmaceuticals reports Q1 results | 2 | Seeking Alpha | ||
| 14.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress | 217 | ACCESS Newswire | Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with... ► Artikel lesen | |
| 14.05. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 06.05. | What's Going On With CNS Pharmaceuticals Stock On Wednesday? | 4 | Benzinga.com | ||
| 04.05. | CNS Pharmaceuticals Stock Surges 263% On Private Placement | 7 | RTTNews | ||
| 04.05. | CNS Pharmaceuticals raises $22.5 million in private placement | 3 | Investing.com | ||
| CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 04.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing | 404 | ACCESS Newswire | The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare PartnersProceeds expected to... ► Artikel lesen | |
| 04.05. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | CNS Pharmaceuticals, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 31.03. | CNS Pharmaceuticals, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 11.03. | CNS Pharma wipes glioblastoma pipeline clean in strategic pivot to fresh neurology, oncology targets | 1 | FierceBiotech | ||
| 11.03. | CNS Pharmaceuticals shifts focus to neurology, oncology assets | 1 | Investing.com | ||
| 11.03. | Strategiewechsel bei CNS Pharmaceuticals: Fokus auf Neurologie und Onkologie | 2 | Investing.com Deutsch | ||
| 11.03. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline | 474 | ACCESS Newswire | Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing marketsStrategic transformation... ► Artikel lesen | |
| 11.03. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 02.03. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.03. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team | 302 | ACCESS Newswire | Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNSNewly formed executive team is committed to execution and company... ► Artikel lesen | |
| 27.02. | CNS Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 17.02. | CNS Pharmaceuticals ernennt drei neue Führungskräfte im Zuge strategischer Neuausrichtung | 3 | Investing.com Deutsch |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,230 | +2,95 % | KAUFKURSE bei Renk und Desert Gold! SCHOCK bei der Evotec Aktie! | Während der Goldpreis schwächelt, befindet sich die Aktie von Desert Gold in einem sauberen Aufwärtstrend. Und geht es nach Analysten, ist eine Vervielfachung möglich. Denn Desert Gold wird in wenigen... ► Artikel lesen | |
| MODERNA | 40,375 | -0,05 % | Moderna Flu Shot Heads To FDA Advisory Panel | ||
| VALNEVA | 2,490 | +0,81 % | Valneva Aktie: Prognose kassiert - die Börse schaut woanders hin | Valneva hat das erste Quartal 2026 mit einem deutlichen Umsatzrückgang abgeschlossen und die Jahresprognose gesenkt. Der Aktienkurs reagierte nicht entscheidend, denn der Markt richtet seinen Blick... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,700 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| VIVOSIM LABS | 1,350 | -0,74 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,760 | -0,92 % | Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? | ||
| ARBUTUS BIOPHARMA | 3,840 | +2,67 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| XOMA ROYALTY | 35,600 | -1,11 % | Ligand Pharmaceuticals und XOMA Royalty passen Fusionsvereinbarung an | ||
| CELLECTAR BIOSCIENCES | 3,200 | 0,00 % | Cellectar Biosciences, Inc. - S-1, General form for registration of securities | ||
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement | OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company", today announced that it has entered into definitive agreements for a registered direct... ► Artikel lesen | |
| NOVOCURE | 15,525 | +0,32 % | Novocure Reports First Quarter 2026 Financial Results | Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio
Optune Pax approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic... ► Artikel lesen | |
| PHARMING | 1,168 | -0,34 % | Pharming Group N.V.: European Commission grants marketing authorization to Pharming's Joenja (leniolisib) - the first approved treatment for APDS in the European Union | Joenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3K,) syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric... ► Artikel lesen | |
| TRAWS PHARMA | 1,510 | +1,34 % | H.C. Wainwright reiterates Buy on Traws Pharma stock, $8 target | ||
| CYTOKINETICS | 65,78 | -0,78 % | Cytokinetics, Incorporated: Cytokinetics to Hold Annual Meeting of Stockholders |
CNS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,340 Euro und damit -1,48 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CNS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.